Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6729478 | 0.93 | KDM4E (0.59) | ACHEKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL10441766 | 0.93 | KDM4E (0.59) | ACHEKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL6725646 | 0.93 | KDM4E (0.59) | ACHEKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL16558026 | 0.93 | KDM4E (0.59) | ACHEKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL9530596 | 0.93 | KDM4E (0.59) | ACHEKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL1357229 | 0.93 | KDM4E (0.59) | ACHEKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL10441646 | 0.93 | KDM4E (0.59) | ACHEKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL17790870 | 0.89 | MEN1 (0.49) | ACHEKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL19525466 | 0.86 | ACHE (0.45) | ACHEKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL16449799 | 0.85 | DGKA (0.65) | KDM4EDUSP3MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016875-B2 | Methods for treating or preventing ophthalmological conditions | IVERIC BIO, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20210317058-A1 | DEGRADABLE POLYMERS AND MONOMERS THEREFOR | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2021-10-14 | — | — | US | disclosed |
| US-20200038342-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | CATABASIS PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-5158808-A | Method of coating with a water borne composition | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1992-10-27 | — | — | US | disclosed |
| US-5039759-A | Water borne high solids coating compositions | TECHNOLOGY CORPORATION UNITED CARBIDE CHEMICALS AND PLASTICS (US) | 1991-08-13 | — | — | US | disclosed |
| EP-0285650-A1 | SOLVENT BORNE HIGH SOLIDS COATING COMPOSITIONS. | UNION CARBIDE CORP (US) | 1988-10-12 | — | — | EP | disclosed |
| WO-1988002766-A1 | SOLVENT BORNE HIGH SOLIDS COATING COMPOSITIONS | UNION CARBIDE CORPORATION (US) | 1988-04-21 | — | — | WO | disclosed |
| EP-0233253-A1 | CARBAMATE COATING COMPOSITIONS | UNION CARBIDE CORPORATION (US) | 1987-08-26 | — | — | EP | disclosed |
| US-4677168-A | Water borne high solids coating compositions | UNION CARBIDE CORPORATION, | 1987-06-30 | — | — | US | disclosed |
| EP-0212380-A2 | Aqueous high solids coating compositions | UNION CARBIDE CORPORATION (US) | 1987-03-04 | — | — | EP | disclosed |
| EP-0211359-A1 | High solids coating compositions | UNION CARBIDE CORPORATION (US) | 1987-02-25 | — | — | EP | disclosed |
| WO-1987000851-A1 | CARBAMATE COATING COMPOSITIONS | UNION CARBIDE CORPORATION (US) | 1987-02-12 | — | — | WO | disclosed |
| EP-0196112-A2 | Aqueous high solids coating compositions | UNION CARBIDE CORPORATION (US) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317058-A1 | DEGRADABLE POLYMERS AND MONOMERS THEREFOR | HDHD5, LTA4H, KYNU | ACHE 1728/4885KDM4E 487/4885DUSP3 4568/4885 |
| US-12016875-B2 | Methods for treating or preventing ophthalmological conditions | ADCY5, MC5R, C5 | ACHE 238/4885KDM4E 3956/4885DUSP3 3459/4885 |
| US-20200038342-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | ATG7, ATG4A, SLC27A1 | ACHE 4662/4885KDM4E 3707/4885DUSP3 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.